Abstract: A method of assessment of microcirculation oscillations comprises illumination of a selected location on non-hairy skin of a human subject in a resting steady condition without any blockage or stimulation of the blood flow with exciting light capable of inducing skin NADH fluorescence signal for a period of time; simultaneously with said illumination detecting, measuring and recording as a function of time the induced NADH fluorescence signal emitted from the said selected location to obtain the time course of the NADH fluorescence signal intensity in the said period of time; and computer implemented steps of: fitting of a baseline about which the NADH fluorescence signal oscillates to the said time course of the NADH fluorescence signal; and determination of a mean squared error of the deviation of the NADH fluorescence signal from the fitted baseline as a parameter of oscillatory function of the skin microcirculation.

Abstract: A method of assessment of microcirculation oscillations comprises illumination of a selected location on non-hairy skin of a human subject in a resting steady condition without any blockage or stimulation of the blood flow with exciting light capable of inducing skin NADH fluorescence signal for a period of time; simultaneously with said illumination detecting, measuring and recording as a function of time the induced NADH fluorescence signal emitted from the said selected location to obtain the time course of the NADH fluorescence signal intensity in the said period of time; and computer implemented steps of: fitting of a baseline about which the NADH fluorescence signal oscillates to the said time course of the NADH fluorescence signal; and determination of a mean squared error of the deviation of the NADH fluorescence signal from the fitted baseline as a parameter of oscillatory function of the skin microcirculation.

Abstract: The use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject with a blood or serum CRP level of less than 10 mg/L. The disclosure also discloses the use of 1-MNA or a pharmaceutically acceptable salt thereof in the amount effective for reducing the blood or serum CRP level for the treatment of diseases such as rheumatoid arthritis, colon cancer, breast cancer, lung cancer, infection, inflammatory bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, renal failure, amyotrophic lateral sclerosis, or a combination thereof.

Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.

Abstract: A method for evaluating vascular endothelium function in a human subject comprises monitoring changes in intensity of NADH fluorescence signal emitted from skin tissue cells of an upper limb of said subject as a function of time, wherein said changes result from reactive hyperaemia caused by blocking and releasing blood flow in the same upper limb of said subject. A system for evaluating vascular endothelium function in a human subject comprises a means for illuminating a skin on an upper limb of said subject with exciting light, a means for measuring intensity of fluorescence signal emitted from the skin and recording changes of said intensity of the fluorescence signal over time; and a restriction means for blocking and releasing blood flow in the upper limb of said subject.

Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.

Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.

Abstract: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.

Abstract: A method for evaluating vascular endothelium function in a human subject comprises monitoring changes in intensity of NADH fluorescence signal emitted from skin tissue cells of an upper limb of said subject as a function of time, wherein said changes result from reactive hyperaemia caused by blocking and releasing blood flow in the same upper limb of said subject. A system for evaluating vascular endothelium function in a human subject comprises a means for illuminating a skin on an upper limb of said subject with exciting light, a means for measuring intensity of fluorescence signal emitted from the skin and recording changes of said intensity of the fluorescence signal over time; and a restriction means for blocking and releasing blood flow in the upper limb of said subject.

Abstract: A method for the treatment or prevention of a cell or tissue damage in a living subject due to the exposure to ionizing radiation is provided, which comprises administration to said subject of a compound of formula (I) wherein R? is H, OH, CONH2 or COCH3, R? is H or CH3, R?? is H or CH3, and X? is a pharmaceutically acceptable counterion, in an amount sufficient to inhibit radiation-induced damage.

Abstract: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.

Abstract: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.

Abstract: The present invention is directed to compositions of nicotinamide derivatives combined with wakame seaweed, wakame extracts, or glycosaminoglycans, and their use in treating skin diseases and disorders.

Abstract: The invention is directed to a method for enhancing prostacyclin levels in a mammal in need thereof, wherein the method includes administering a quaternary pyridinium salt of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion.

Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.

Abstract: The invention relates to a method for inhibiting and/or preventing formation of cancer metastases and secondary malignant cancers by administration to a subject of an effective amount of a quaternary pyridinium salt of formula I wherein R? is selected from the group consisting of H, OH, CONH2, COCH3, R? is selected from the group consisting of H, CH3, R?? represents H or CH3, and X? is a pharmaceutically acceptable counterion.

Abstract: The invention relates to a method for the treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury comprising the administration to a patient in a need of such treatment or prevention of a therapeutically or prophylactically effective amount of a compound selected from the group consisting of: wherein R represents hydrogen atom, CH3, OH, pyridyl (C5H4N), 1-methylpyridyl (C5H4N—CH3) or pyridyl substituted with hydroxy group ((OH)C5H3N), and X represents a physiologically acceptable counterion.

Abstract: The invention is directed to a method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia by administration of a 1-methylnicotinamide salt.

Abstract: The invention relates to the novel N?-nitroxyalkylnicotinamide derivatives represented by the general formula I wherein R1 is C1-C4 alkyl; R2 is hydrogen. C1-C4 alkyl, CH2OH or CH2ONO2; R3 is ONO2, CH2ONO2 or OH; provided that when R3 is OH, R2 is CH2ONO2; and X? is an organic or inorganic anion; as well as pharmaceutical compositions thereof and their use as a medicament, in particular, in the treatment of diseases of the cardiovascular system.

Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.